Linagliptin
Antidiabetic agent. Highly potent and selective competitive inhibitor of dipeptidyl-peptidase 4 (DPP4; DPP IV; CD26), an enzyme that degrades, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Prevents the inactivation of endogenous GLP-1 and GIP. Shown to restore beta cell function and survival in human isolated islets through GLP-1 stabilization. Improves insulin sensitivity. Anti-inflammatory compound.
| Catalog Number | AG-CR1-3618-M050 |
| Alternative Name(s) | 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione; BI-1356 |
| Research Area | Biochemicals, Inflammation, Metabolism, Obesity |
| Molecular Formula | C25H28N8O2 |
| CAS# | 668270-12-0 |
| Purity | >98% |
| Inchi | InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1 |
| Inchi Key | LTXREWYXXSTFRX-QGZVFWFLSA-N |
| SMILES | CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1 |
| Size | 50 mg |
| Supplier Page | http://www.adipogen.com/ag-cr1-3618/linagliptin.html |